SRA's number for the day: 19
This article was originally published in SRA
A total of 19 pharmaceutical companies between 2009 and 2012 failed to submit one or more annual reports on deferred measures relating to paediatric investigation plans (PIPs) for authorized medicines, as required by the EU Paediatric Regulation1.
You may also be interested in...
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.